Physician profile
Kenneth B Goldstein
NPI 1659473239
$1,535.46
in general payments reported to CMS, 2019-2025
24 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.28 · 2020: $56.79 · 2021: $211 · 2022: $94.38 · 2023: $268 · 2024: $379 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $283.57 | 2020-2024 | Mounjaro |
| Exact Sciences Corporation | $167.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $136.90 | 2019-2025 | Wegovy |
| Pfizer INC. | $115.26 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.81 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.96 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Collegium Pharmaceutical, INC. | $98.83 | 2024-2025 | Belbuca, Xtampza |
| Otsuka America Pharmaceutical, INC. | $81.46 | 2025 | Rexulti |
| Eisai INC. | $77.90 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $77.38 | 2024-2025 | Airsupra, Farxiga |
| Sunovion Pharmaceuticals INC. | $36.86 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $29.18 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.48 | 2023 | Rexulti |
| Abbvie INC. | $24.54 | 2021 | |
| Corcept Therapeutics | $21.17 | 2025 | Korlym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.36 | 2024 | Proclaim |
| Novartis Pharmaceuticals Corporation | $19.23 | 2023 | |
| Teleflex LLC | $16.98 | 2024 | Urolift |
| Hologic Sales and Service, LLC | $16.58 | 2025 | Aptima |
| Lundbeck LLC | $16.44 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $15.82 | 2025 | Opsumit, Uptravi |
| Amgen INC. | $14.85 | 2020 | |
| Glaxosmithkline, LLC. | $13.11 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.